Thats honestly a fairly tough question
We know that roughly 51% of Americans meet the diagnostic criteria for GLP-1 use, and then on top of that, there are several randomized control trials underway right now looking at how GLP-1s may have a benefit in other diseases, explains Whitney Evans, director of nutrition and scientific affairs at Danone North America
But in order to get these specialty treatments, you had to go to a fancy doctors office and pay premium prices
The takeaway for buyers is straightforward: high CoV = comparison shopping pays
In this blog post, well explore the reasons behind the semaglutide and tirzepatide shortage and how compounded formulations of these medications can offer a promising avenue for weight loss
These updates are posted in the 6th (time-in-range), 9 th and 10 th (Trulicity), and 13th (Victoza) chapters